Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings

Abstract

Objective This study aims to systematically validate the performance of surrogate endpoints in phase II and III clinical trials for NSCLC patients under various trial settings. Methods A literature search retrieved all registered phase II and III trials of NSCLC patients in which OS, with at least one of ORR and PFS, were reported. Associations between surrogate and true endpoints were assessed on two levels. On the arm level, three pairs of correlations, i.e., ORR vs. median OS, ORR vs. median PFS, and median PFS vs. median OS, were analysed using Spearman’s rho. On the trial level, similarly, three pairs of correlations, i.e., ΔORR vs. HR of OS, ΔORR vs. HR of PFS, and HR of PFS vs. HR of OS, were analysed using Spearman’s rho and weighted linear regression model respectively. Finally, sensitivity analyses were performed to explore surrogacy under various trial settings. Results At arm level, three pairs of correlations are all high (Spearman’s rho = 0.700, 0.831, 0.755, respectively). At trial level, there is a low correlation between ΔORR and HR of OS, a high correlation between ΔORR and HR of PFS and a moderate correlation between HR of PFS and HR of OS (Spearman’s rho = 0.462, 0.764, 0.584, respectively). In the sensitivity analysis, we find correlations between surrogate and true endpoints vary by different trial settings. It is noteworthy that the strength of surrogacy of these intermediate endpoints in targeted therapy is greater than that in immunotherapy. Conclusion According to the arm-level and trial level-analysis, we suggest that in phase II and III trials of targeted therapy and immunotherapy for NSCLC patients: 1) ORR lacks validity for the surrogacy of OS, excluding in first-line therapy, and 2) ORR may be an appropriate surrogate endpoint for PFS, and 3) PFS may be considered a modest surrogacy for OS, with better performance in first-line therapy trials. Moreover, to provide more convincing evidence of surrogacy of the surrogate endpoints, patient-level analyses are in desperate need.

Can blood-based markers predict RECIST progression in non-small cell lung cancer treated with immunotherapy?

“…Indeed, the relationship between PFS and OS is complex and varies across different cancer types and therapeutics. In the context of NSCLC and immunotherapy or targeted therapies, previous studies suggest, at most, moderate potential for PFS to be used as a surrogate of OS (Ye et al 2020 ; Shameer et al 2021 ; Hua et al 2022 ), while strongly advocating for the need for patient-level analyses, where true surrogacy can be evaluated.…”

Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE‐158 study

“…ORR was selected as the primary end point for this single‐arm study. Some evidence has suggested that, in phase 2 studies evaluating immune checkpoint inhibitors, ORR may not correlate with PFS and OS and underestimate clinical benefit 25,26 . Prior studies of targeted therapies in patients with thyroid cancer have reported 2‐year OS rates of approximately 60% 3,4,27 .…”

PLEKHG2 Promotes NSCLC Cell Growth by Increasing Glycolysis via Activated PI3K/AKT Pathway

“…Although the prognosis of NSCLC patients has been improving with continuing breakthroughs in research into driver genes and the availability of several new therapeutic options [15][16][17]. However, rapid drug resistance due to tumor heterogeneity is also creating new challenges in NSCLC [18,19].…”